drugset / Trial / NCT06238167
Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with tislelizumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or tegafur-gimeracil-oteracil potassium + oxaliplatin (SOX therapy) in PD-L1 CPS positive, elderly (≥70years old), pStage III gastric cancer (including esophagogastric junction cancer) after D2 dissection.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2026-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxaliplatin | Small molecule | 78 mg/m2 | — |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | — |
| Subject | tegafur-gimeracil-oteracil potassium | Small molecule | 40 mg | — |
| Subject | tegafur-gimeracil-oteracil potassium | Small molecule | 50 mg | — |
| Subject | tegafur-gimeracil-oteracil potassium | Small molecule | 60 mg | — |